NASDAQ:CMPX Compass Therapeutics Q3 2026 Earnings Results & Report $0.84 +0.01 (+0.61%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Compass Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.15 versus the -$0.1264 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Compass Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.1264Beat/MissMissed by -$0.0236One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCompass Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$229 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Compass Therapeutics Q3 2026 Earnings FAQ Did Compass Therapeutics beat earnings estimates for Q3 2026? Compass Therapeutics (NASDAQ:CMPX) reported earnings of -$0.15 per share for Q3 2026, missing the consensus estimate of -$0.1264. The report was announced on Monday, November 9, 2026. Compass Therapeutics Earnings HeadlinesMacro and Geopolitical Risks Threaten Compass Therapeutics’ Costs, Liquidity, and Clinical OperationsNovember 10 at 1:11 AM | tipranks.comCompass Therapeutics Advances CTX-471 Cancer Study as Investors Await Early DataNovember 9 at 11:30 AM | tipranks.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate UpdateNovember 9 at 8:00 AM | globenewswire.comCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual MeetingNovember 6, 2026 | globenewswire.comCompass Therapeutics to Participate in Upcoming November Investor EventsNovember 2, 2026 | globenewswire.comSee More Compass Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email. Email Address About Compass TherapeuticsCompass Therapeutics (NASDAQ:CMPX) is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer. Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells. Compass Therapeutics has investigated CTX-471 as a standalone treatment and in combination with other cancer immunotherapies, including checkpoint inhibitors. Compass Therapeutics was founded in 2014 and is based in Boston, Massachusetts. The company’s programs are primarily directed toward oncology applications and are being developed through clinical research and collaborations. Dr. Thomas Schuetz, a co-founder of the company, has served as its chief executive officer.View Compass Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
